Virological Suppression Sustained With Very Early ART in Neonates With HIV-1

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 12, 2023.

By Elana Gotkine HealthDay Reporter

TUESDAY, Dec. 12, 2023 -- For neonates with in utero HIV-1, very early antiretroviral therapy (ART) can achieve sustained virological suppression, according to a study published online Dec. 4 in The Lancet HIV.

Deborah Persaud, M.D., from Johns Hopkins University School of Medicine in Baltimore, and colleagues enrolled infants at 30 research clinics in 11 countries into two cohorts to examine whether very early ART in neonates would restrict HIV-1 reservoirs. Infants at least 34 weeks of gestational age at high risk for in utero HIV-1 with either untreated maternal HIV-1 (cohort 1; 440 infants) or receiving preemptive triple antiretroviral prophylaxis outside of the study (cohort 2; 20 infants) were included. Of these infants, 34 from cohort 1 and 20 from cohort 2 had confirmed in utero HIV-1 and initiated three-drug nevirapine-based ART (cohort 1) and three-drug nevirapine-based prophylaxis then three-drug nevirapine-based ART following HIV diagnosis by age 10 days (cohort 2).

The researchers found that the estimated probability of maintaining undetectable plasma RNA through two years was 33 and 57 percent in cohorts 1 and 2, respectively. No detected HIV-1 DNA was seen among 64 and 71 percent of the 11 and seven infants in cohorts 1 and 2, respectively, who maintained protocol-defined virological control criteria through to study week 108. At week 108, 83 percent of 12 infants in cohort 1 and 100 percent of seven infants in cohort 2 tested HIV-1 antibody-negative.

"Neonatal ART following in-utero HIV-1 transmission is feasible and can reduce reservoir size," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-13 02:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords